Technical Analysis for PGNX - Progenics Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade B 5.35 -2.55% -0.14
PGNX closed down 2.55 percent on Friday, September 13, 2019, on 2.0 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical PGNX trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish -2.55%
Upper Bollinger Band Walk Strength -2.55%
Wide Bands Range Expansion -2.55%
Overbought Stochastic Strength -2.55%
Upper Bollinger Band Touch Strength -2.55%
Pocket Pivot Bullish Swing Setup -3.25%
Upper Bollinger Band Walk Strength -3.25%

Older signals for PGNX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404, which is in Phase II testing for imaging agent for prostate cancer; and Azedra for the treatment of pheochromocytoma and paraganglioma, and Neuroblastoma. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as on the neovasculature of various other types of solid tumors. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.
Medicine Chemistry Biotechnology Cancer Pain Imaging Oncology Solid Tumors Cancers Prostate Cancer Morphinans Cyclopropanes Neuroblastoma Phenols Adc Constipation Salix Pharmaceuticals
Is PGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.615
52 Week Low 3.42
Average Volume 876,179
200-Day Moving Average 4.7168
50-Day Moving Average 4.8584
20-Day Moving Average 4.525
10-Day Moving Average 4.947
Average True Range 0.295
ADX 24.07
+DI 32.6157
-DI 21.0036
Chandelier Exit (Long, 3 ATRs ) 4.745
Chandelier Exit (Short, 3 ATRs ) 4.305
Upper Bollinger Band 5.6772
Lower Bollinger Band 3.3728
Percent B (%b) 0.86
BandWidth 50.925967
MACD Line 0.2039
MACD Signal Line 0.0472
MACD Histogram 0.1567
Fundamentals Value
Market Cap 375.94 Million
Num Shares 70.3 Million
EPS -0.06
Price-to-Earnings (P/E) Ratio -89.17
Price-to-Sales 6.47
Price-to-Book 5.52
PEG Ratio -0.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.06
Resistance 3 (R3) 6.06 5.82 5.94
Resistance 2 (R2) 5.82 5.64 5.82 5.90
Resistance 1 (R1) 5.59 5.53 5.47 5.59 5.86
Pivot Point 5.35 5.35 5.30 5.35 5.35
Support 1 (S1) 5.12 5.17 5.00 5.12 4.84
Support 2 (S2) 4.88 5.06 4.88 4.80
Support 3 (S3) 4.65 4.88 4.76
Support 4 (S4) 4.65